With respect to TNF-α blockers, infliximab may improve endothelial function in RA after 12 weeks of therapy [45], suggesting that inflammation is a mediator of endothelial dysfunction, although such beneficial effects do not appear to sustain for a long time [46,47]. This evidence concerns the gene TNF and rheumatoid arthritis.